[Federal Register Volume 60, Number 144 (Thursday, July 27, 1995)]
[Notices]
[Pages 38564-38565]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-18503]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces a forthcoming meeting of a public
advisory committee of the Food and Drug Administration (FDA). This
notice also summarizes the procedures for the meeting and methods by
which interested persons may participate in open public hearings before
FDA's advisory committees.
FDA has established an Advisory Committee Information Hotline (the
hotline) using a voice-mail telephone system. The hotline provides the
public with access to the most current information on FDA advisory
committee meetings. The advisory committee hotline, which will
disseminate current information and information updates, can be
accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory
committee is assigned a 5-digit number. This 5-digit number will appear
in each individual notice of meeting. The hotline will enable the
public to obtain information about a particular advisory committee by
using the committee's 5-digit number. Information in the hotline is
preliminary and may change before a meeting is actually held. The
hotline will be updated when such changes are made.
MEETING: The following advisory committee meeting is announced:
Subcommittee Meeting of the National Task Force on AIDS Drug
Development on Drug Development Issues
Date, time, and place. September 13 and 14, 1995, 8:30 a.m.,
Gaithersburg Hilton Hotel, Grand Ballroom, 629 Perry Pkwy.,
Gaithersburg, MD. A limited number of overnight accommodations have
been reserved at the Gaithersburg Hilton Hotel. Attendees requiring
overnight accommodations may contact the hotel at 301-977-8900 and
reference the task force. Interested persons are encouraged to register
early because space is limited.
Type of meeting and contact person. Open subcommittee discussion,
September 13, 1995, 8:30 a.m. to 11:45 a.m.; open public hearing, 11:45
a.m. to 12:15 p.m., unless public participation does not last that
long; open subcommittee discussion, 12:15 p.m. to 4:45 p.m.; open
subcommittee discussion, September 14, 1995, 8:30 a.m. to 11:45 a.m.;
open public hearing, 11:45 a.m. to 12:15 p.m., unless public
participation does not last that long; Nancy L. Stanisic, Office of
AIDS and Special Health Issues (HF-12), Food and Drug Administration,
5600 Fishers Lane, Rockville, MD 20857, 301-443-0104, or FDA Advisory
Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), National Task Force on AIDS Drug Development,
code 12602.
General functions of the task force. The task force shall identify
any barriers and provide creative options for the rapid development and
evaluation of treatments for human immunodeficiency virus (HIV)
infection and its sequelae. It also advises on issues related to such
barriers, and provides options for the elimination of these barriers.
Open subcommittee discussion. The subcommittee will review,
discuss, and clarify issues concerning the
[[Page 38565]]
investigational new drug applications and submissions to the National
Institutes of Health's Recombinant DNA Advisory Committee as it relates
to gene therapy. Representatives from FDA's Center for Biologics
Evaluation and Research and the National Institutes of Health's Office
of Recombinant DNA Activities will make presentations and answer
questions concerning the application process.
Agenda--Open public hearing. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the task force. Those desiring to make formal presentations should
notify the contact person before September 6, 1995, and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time required to make their comments.
FDA public advisory committee meetings may have as many as four
separable portions: (1) An open public hearing, (2) an open committee
discussion, (3) a closed presentation of data, and (4) a closed
committee deliberation. Every advisory committee meeting shall have an
open public hearing portion. Whether or not it also includes any of the
other three portions will depend upon the specific meeting involved.
There are no closed portions for the meetings announced in this notice.
The dates and times reserved for the open portions of each committee
meeting are listed above.
The open public hearing portion of each meeting shall be at least 1
hour long unless public participation does not last that long. It is
emphasized, however, that the 1 hour time limit for an open public
hearing represents a minimum rather than a maximum time for public
participation, and an open public hearing may last for whatever longer
period the committee chairperson determines will facilitate the
committee's work.
Public hearings are subject to FDA's guideline (subpart C of 21 CFR
part 10) concerning the policy and procedures for electronic media
coverage of FDA's public administrative proceedings, including hearings
before public advisory committees under 21 CFR part 14. Under 21 CFR
10.205, representatives of the electronic media may be permitted,
subject to certain limitations, to videotape, film, or otherwise record
FDA's public administrative proceedings, including presentations by
participants.
Meetings of advisory committees shall be conducted, insofar as is
practical, in accordance with the agenda published in this Federal
Register notice. Changes in the agenda will be announced at the
beginning of the open portion of a meeting.
Any interested person who wishes to be assured of the right to make
an oral presentation at the open public hearing portion of a meeting
shall inform the contact person listed above, either orally or in
writing, prior to the meeting. Any person attending the hearing who
does not in advance of the meeting request an opportunity to speak will
be allowed to make an oral presentation at the hearing's conclusion, if
time permits, at the chairperson's discretion.
The agenda, the questions to be addressed by the committee, and a
current list of committee members will be available at the meeting
location on the day of the meeting.
Transcripts of the open portion of the meeting may be requested in
writing from the Freedom of Information Office (HFI-35), Food and Drug
Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857,
approximately 15 working days after the meeting, at a cost of 10 cents
per page. The transcript may be viewed at the Dockets Management Branch
(HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr.,
Rockville, MD 20857, approximately 15 working days after the meeting,
between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary
minutes of the open portion of the meeting may be requested in writing
from the Freedom of Information Office (address above) beginning
approximately 90 days after the meeting.
This notice is issued under section 10(a)(1) and (2) of the Federal
Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR
part 14) on advisory committees.
Dated: July 19, 1995.
Linda A. Suydam,
Interim Deputy Commissioner for Operations.
[FR Doc. 95-18503 Filed 7-26-95; 8:45 am]
BILLING CODE 4160-01-F
